FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297426682> ?p ?o ?g. }

• W4297426682 abstract "Background The complete resection rate of pancreatic cancer has increased because of the advent of efficacious first-line treatments for unresectable pancreatic cancer. Still, strategies regarding adjuvant therapy after neoadjuvant FOLFIRINOX treatment remain to be established. Methods Data on 144 patients with borderline resectable and locally advanced pancreatic cancer who underwent resection after neoadjuvant FOLFIRINOX between January 2013 and April 2021 were retrospectively reviewed. Results Among the study patients, 113 patients (78.5%) were diagnosed with borderline resectable pancreatic cancer and 31 patients (21.5%) were diagnosed with locally advanced pancreatic cancer. Seventy-five patients (52.1%) received radiotherapy before surgery. After radical resection, 84 patients (58.3%) received 5-fluorouracil-based adjuvant therapy and 60 patients (41.7%) received non-5-fluorouracil-based adjuvant therapy. Adjuvant therapy with 5-fluorouracil-based regimen [hazard ratio (HR), 0.43 (95% CI, 0.21–0.87); p = 0.019], preoperative assessment as locally advanced pancreatic cancer [HR, 2.87 (95% CI, 1.08–7.64); p = 0.035], positive resection margin [HR, 3.91 (95% CI, 1.71–8.94); p = 0.001], and presence of pathologic lymph node involvement [HR, 2.31 (95% CI, 1.00–5.33), p = 0.050] were associated with decreased recurrence-free survival. Adjuvant therapy with 5-fluorouracil-based regimen [HR, 0.35 (95% CI, 0.15–0.84); p = 0.018], positive resection margin [HR, 4.14 (95% CI, 1.75–9.78); p = 0.001], presence of pathologic lymph node involvement [HR, 3.36 (95% CI, 1.23–9.15); p = 0.018], poor differentiation [HR, 5.69 (95% CI, 1.76–18.36); p = 0.004], and dose reduction during adjuvant therapy [HR, 1.78 (95% CI, 1.24–24.37); p = 0.025] were associated with decreased overall survival. Conclusions The 5-fluorouracil-based adjuvant therapy seems to be the proper adjuvant therapy for patients who received neoadjuvant FOLFIRINOX for borderline resectable and locally advanced pancreatic cancer." @default.
• W4297426682 created "2022-09-28" @default.
• W4297426682 creator A5011931629 @default.
• W4297426682 creator A5024933931 @default.
• W4297426682 creator A5029085217 @default.
• W4297426682 creator A5045716213 @default.
• W4297426682 creator A5047000057 @default.
• W4297426682 creator A5052238082 @default.
• W4297426682 creator A5058827533 @default.
• W4297426682 creator A5067818633 @default.
• W4297426682 creator A5080250415 @default.
• W4297426682 creator A5080466465 @default.
• W4297426682 creator A5081012545 @default.
• W4297426682 creator A5085553146 @default.
• W4297426682 date "2022-09-20" @default.
• W4297426682 modified "2023-10-14" @default.
• W4297426682 title "Proper adjuvant therapy in patients with borderline resectable and locally advanced pancreatic cancer who had received neoadjuvant FOLFIRINOX" @default.
• W4297426682 cites W1190748217 @default.
• W4297426682 cites W2012005360 @default.
• W4297426682 cites W2044211072 @default.
• W4297426682 cites W2048000318 @default.
• W4297426682 cites W2064160049 @default.
• W4297426682 cites W2123372880 @default.
• W4297426682 cites W2129884672 @default.
• W4297426682 cites W2137189854 @default.
• W4297426682 cites W2138582833 @default.
• W4297426682 cites W2151253787 @default.
• W4297426682 cites W2330075233 @default.
• W4297426682 cites W2373606074 @default.
• W4297426682 cites W2412717755 @default.
• W4297426682 cites W2502134830 @default.
• W4297426682 cites W2573152477 @default.
• W4297426682 cites W2581973599 @default.
• W4297426682 cites W2799575632 @default.
• W4297426682 cites W2804908082 @default.
• W4297426682 cites W2903623792 @default.
• W4297426682 cites W2907437794 @default.
• W4297426682 cites W2911188335 @default.
• W4297426682 cites W2912196744 @default.
• W4297426682 cites W2939930585 @default.
• W4297426682 cites W2946040614 @default.
• W4297426682 cites W2955098550 @default.
• W4297426682 cites W3002916325 @default.
• W4297426682 cites W3083989780 @default.
• W4297426682 cites W3128594599 @default.
• W4297426682 cites W3202367927 @default.
• W4297426682 cites W4251725022 @default.
• W4297426682 doi "https://doi.org/10.3389/fonc.2022.945829" @default.
• W4297426682 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36226066" @default.
• W4297426682 hasPublicationYear "2022" @default.
• W4297426682 type Work @default.
• W4297426682 citedByCount "1" @default.
• W4297426682 countsByYear W42974266822023 @default.
• W4297426682 crossrefType "journal-article" @default.
• W4297426682 hasAuthorship W4297426682A5011931629 @default.
• W4297426682 hasAuthorship W4297426682A5024933931 @default.
• W4297426682 hasAuthorship W4297426682A5029085217 @default.
• W4297426682 hasAuthorship W4297426682A5045716213 @default.
• W4297426682 hasAuthorship W4297426682A5047000057 @default.
• W4297426682 hasAuthorship W4297426682A5052238082 @default.
• W4297426682 hasAuthorship W4297426682A5058827533 @default.
• W4297426682 hasAuthorship W4297426682A5067818633 @default.
• W4297426682 hasAuthorship W4297426682A5080250415 @default.
• W4297426682 hasAuthorship W4297426682A5080466465 @default.
• W4297426682 hasAuthorship W4297426682A5081012545 @default.
• W4297426682 hasAuthorship W4297426682A5085553146 @default.
• W4297426682 hasBestOaLocation W42974266821 @default.
• W4297426682 hasConcept C121608353 @default.
• W4297426682 hasConcept C126322002 @default.
• W4297426682 hasConcept C141071460 @default.
• W4297426682 hasConcept C143998085 @default.
• W4297426682 hasConcept C159110652 @default.
• W4297426682 hasConcept C207103383 @default.
• W4297426682 hasConcept C2777148230 @default.
• W4297426682 hasConcept C2777982462 @default.
• W4297426682 hasConcept C2778132481 @default.
• W4297426682 hasConcept C2778292576 @default.
• W4297426682 hasConcept C2780210213 @default.
• W4297426682 hasConcept C2780259306 @default.
• W4297426682 hasConcept C2780456651 @default.
• W4297426682 hasConcept C2780849966 @default.
• W4297426682 hasConcept C2781413609 @default.
• W4297426682 hasConcept C44249647 @default.
• W4297426682 hasConcept C509974204 @default.
• W4297426682 hasConcept C526805850 @default.
• W4297426682 hasConcept C530470458 @default.
• W4297426682 hasConcept C71924100 @default.
• W4297426682 hasConcept C90924648 @default.
• W4297426682 hasConceptScore W4297426682C121608353 @default.
• W4297426682 hasConceptScore W4297426682C126322002 @default.
• W4297426682 hasConceptScore W4297426682C141071460 @default.
• W4297426682 hasConceptScore W4297426682C143998085 @default.
• W4297426682 hasConceptScore W4297426682C159110652 @default.
• W4297426682 hasConceptScore W4297426682C207103383 @default.
• W4297426682 hasConceptScore W4297426682C2777148230 @default.
• W4297426682 hasConceptScore W4297426682C2777982462 @default.
• W4297426682 hasConceptScore W4297426682C2778132481 @default.
• W4297426682 hasConceptScore W4297426682C2778292576 @default.
• W4297426682 hasConceptScore W4297426682C2780210213 @default.
• W4297426682 hasConceptScore W4297426682C2780259306 @default.

• next